Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$8.02−0.60 (-6.96%)
Close on Nov 12, 2026Market cap $291.06MP/E –Yield –
Evommune EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Evommune's EPS for the twelve months ending Sep 30, 2025 was -$40.89. For fiscal 2025 it was -$11.22.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.22 | – |
| FY2024 | Dec 31, 2024 | -$45.29 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.85 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.89 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.64 | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.07 | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.80 | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.48 | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.54 | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.47 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?